Premium
Effect of platelet‐activating factor on lipoprotein lipase and blood lipids
Author(s) -
Mimura Keiji,
Yukawa Susumu,
Mori Yoshio,
Okada Kazuya,
Mune Masatoshi,
Nishikawa Osamu,
Hibino Akira,
Sonobe Miyahiko,
Goto Tetuya,
Nomoto Hiroshi
Publication year - 1991
Publication title -
lipids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.601
H-Index - 120
eISSN - 1558-9307
pISSN - 0024-4201
DOI - 10.1007/bf02536510
Subject(s) - lipoprotein lipase , platelet activating factor , chemistry , endocrinology , medicine , phospholipid , lipase , antagonist , lipidology , clinical chemistry , heparin , triglyceride lipase , blood plasma , enzyme , biochemistry , receptor , membrane
Abstract We investigated the effect of platelet‐activating factor (PAF) and of the PAF specific antagonist CV‐6209 on plasma lipid metabolism, and particularly on post‐heparin plasma lipolytic activity in male Wistar rats. Lipoprotein lipase (LPL) activity was enhanced by intravenous injection of PAF before intravenous injection of heparin when the PAF dose was low (0.2 μg/kg). PAF activated hepatic triacylglycerol lipase (HTGL) activity dose‐dependently. Plasma triacylglycerols (TG) significantly decreased with the activation of LPL and/or HTGL. Plasma total cholesterol (TC) and phospholipid (PL) levels decreased at a low dose of PAF (0.2 μg/kg), but increased when higher doses were used. The PAF antagonist CV‐6209 partially reversed the PAF induced effects on HTGL, TC and PL.